Himension Capital Singapore PTE. LTD. Has $1.31 Million Holdings in Moderna, Inc. (NASDAQ:MRNA)

Himension Capital Singapore PTE. LTD. boosted its stake in Moderna, Inc. (NASDAQ:MRNA) by 201.0% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 31,598 shares of the company’s stock after buying an additional 21,102 shares during the period. Himension Capital Singapore PTE. LTD.’s holdings in Moderna were worth $1,314,000 at the end of the most recent reporting period.

Other institutional investors have also bought and sold shares of the company. Wilmington Savings Fund Society FSB raised its stake in Moderna by 295.0% during the fourth quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company’s stock worth $33,000 after acquiring an additional 587 shares in the last quarter. Compass Planning Associates Inc acquired a new stake in shares of Moderna during the 4th quarter worth about $37,000. Venturi Wealth Management LLC lifted its holdings in Moderna by 286.2% during the 4th quarter. Venturi Wealth Management LLC now owns 896 shares of the company’s stock valued at $37,000 after purchasing an additional 664 shares during the last quarter. Crowley Wealth Management Inc. bought a new stake in Moderna during the fourth quarter worth about $41,000. Finally, MassMutual Private Wealth & Trust FSB grew its stake in Moderna by 58.2% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 1,057 shares of the company’s stock worth $44,000 after buying an additional 389 shares during the last quarter. Institutional investors and hedge funds own 75.33% of the company’s stock.

Wall Street Analysts Forecast Growth

MRNA has been the subject of a number of research analyst reports. JPMorgan Chase & Co. cut their target price on shares of Moderna from $40.00 to $33.00 and set an “underweight” rating for the company in a research note on Friday, March 21st. Royal Bank of Canada reissued a “sector perform” rating and issued a $40.00 price objective on shares of Moderna in a research note on Tuesday, February 18th. Morgan Stanley lowered their target price on Moderna from $70.00 to $38.00 and set an “equal weight” rating for the company in a research note on Wednesday, January 15th. UBS Group cut their price target on Moderna from $96.00 to $78.00 and set a “buy” rating for the company in a report on Wednesday, February 19th. Finally, Argus lowered shares of Moderna from a “buy” rating to a “hold” rating in a report on Wednesday, December 18th. Four investment analysts have rated the stock with a sell rating, sixteen have assigned a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Moderna presently has an average rating of “Hold” and an average price target of $59.00.

Moderna Trading Down 2.4 %

Shares of MRNA opened at $25.11 on Friday. The stock has a market cap of $9.71 billion, a P/E ratio of -2.71 and a beta of 2.23. The stock’s 50-day moving average price is $33.55 and its two-hundred day moving average price is $42.80. Moderna, Inc. has a 1 year low of $23.76 and a 1 year high of $170.47.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.